Beyond the 0.5 ng/mL Threshold: What the Bemotrizinol Record Actually Shows

A paper titled "Beyond the 0.5 ng/mL Threshold: Reframing Maximal Usage Trials After Bemotrizinol" went online October 12, 2026, in the Journal of the American Academy of Dermatology, credited to Mackenzie K. Joe, Ananya Sampathkumar, Anita Prabhu, Cathryn Bigham, Alexander J. Jafari, and Carina A. Wasko. The full text sits behind a paywall. What follows is built from the regulatory record the title points to, not from the authors' own argument, which can't be verified beyond its title and byline.

Bemotrizinol has been sold in Europe, Australia, and Asia since the early 2000s, at concentrations up to 10 percent, after BASF first filed it with the FDA in 2005. The US version stalled for two decades inside the agency's sunscreen monograph process. That changed on June 9, 2026, when the FDA finalized an order adding bemotrizinol at 6 percent, marketed as BASF's Tinosorb S and dsm-firmenich's PARSOL Shield, to the OTC monograph. It was the first new US sunscreen active ingredient since 1999. The order took effect August 9, 2026, and Ultra Violette put the first US bemotrizinol product on shelves August 31, 2026.

The approval rests on a two-part study registered as NCT05277376: a pilot pharmacokinetic study followed by a randomized, open-label, three-arm maximal usage trial in 162 adults using market-image 6 percent formulations, with 22 plasma draws per subject. Of 3,722 total samples, 113, about 3 percent, exceeded the 0.5 ng/mL systemic absorption threshold that triggers mandatory nonclinical toxicology testing. Five of the 162 subjects had no quantifiable plasma concentration in any sample. The FDA's own clinical pharmacology and clinical safety summaries report no evidence of accumulation or steady-state buildup across the dosing period.

The 0.5 ng/mL figure itself came from a different exercise than measuring any specific filter's risk. The FDA has described it as "somewhat arbitrary," derived from the plasma concentration below which a single dose of an unknown compound would carry less than a one-in-100,000 theoretical carcinogenic risk. That math produced a screening trigger for further study, not a safety verdict on any ingredient that crosses it.

The trigger itself traces to a 2019 JAMA-published maximal usage trial on avobenzone, oxybenzone, octocrylene, and ecamsule, the study that established mandatory testing above 0.5 ng/mL as FDA policy. Critics in the cosmetics trade press, including a Cosmetics & Toiletries analysis, argued that trial ran panels as small as six subjects per sunscreen arm and applied product at 2 mg/cm2, a density the piece called far heavier than what most consumers use on their skin. Those two design choices, panel size and application rate, are the same variables a bemotrizinol-focused reframing of MUsT methodology would have to confront.

A toxicologist quoted by the Science Media Centre in reaction to that earlier research agreed that measurable absorption above the threshold doesn't equal demonstrated harm. The same source said that agreement doesn't close the question of further scrutiny for ingredients that cross it. That tension, between a sub-threshold result functioning as reassurance and a sub-threshold result functioning as the end of inquiry, is the fork the JAAD title gestures toward without the retrievable text to say which way it lands.

Bemotrizinol's own numbers could support either reading. A 3 percent exceedance rate across 3,722 samples, with five subjects showing no detectable drug at all, reads as evidence the threshold correctly screens out a low-absorption filter. It could just as easily serve as a case study for why a single population-wide cutoff treats near-zero absorption and borderline absorption as the same regulatory event. Nothing in the trial registry entry or the FDA's support documents states which conclusion the JAAD authors draw, and the documents checked here don't settle the question either way.

An FDA internal scientific review document dated December 9, 2025, sits in the public docket for OTC000039, the bemotrizinol monograph file, ahead of the June 2026 order. It hasn't been reviewed for this piece. Bemotrizinol's current FDA approval covers use starting at 6 months of age, and the trial underlying that approval enrolled adults. PARSOL Shield's 18-month US market exclusivity window, which began running when the order took effect in August 2026, will close before any pediatric-specific absorption data of the same design exists.